Hoffbrand B I, Bingley P J, Oppenheimer S M, Sheldon C D
Department of Medicine, Whittington Hospital, London, UK.
J Neurol Neurosurg Psychiatry. 1988 Sep;51(9):1213-4. doi: 10.1136/jnnp.51.9.1213.
Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.
在一项急性中风的双盲安慰剂对照试验中，每天通过肌肉注射给予神经节苷脂GM1（100毫克），持续28天。在6个月的随访期内，匹配良好的对照组和治疗组之间未检测到显著差异。尽管研究的患者数量较少，但这些发现被认为表明，在所使用的剂量和给药途径下，GM1不太可能对急性中风的治疗有价值。
